Hyperion Therapeutics Inc (HPTX)

45.99
0.02 0.04
Prev Close 45.97
Open 45.98
Day Low/High 45.98 / 46.02
52 Wk Low/High 20.23 / 46.96
Volume 308.10K
Avg Volume 538.10K
Exchange
Shares Outstanding 20.98M
Market Cap 964.71M
EPS -0.31
Div & Yield N.A. (N.A)

Latest News

HPTX INVESTOR ALERT: The Law Offices Of Vincent Wong Launches An Investigation Of The Board Of Directors Of Hyperion Therapeutics, Inc. In Connection With The Sale Of The Company To Horizon Pharma

HPTX INVESTOR ALERT: The Law Offices Of Vincent Wong Launches An Investigation Of The Board Of Directors Of Hyperion Therapeutics, Inc. In Connection With The Sale Of The Company To Horizon Pharma

The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Hyperion Therapeutics, Inc.

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation Of The Board Of Directors Of Hyperion Therapeutics, Inc.

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation Of The Board Of Directors Of Hyperion Therapeutics, Inc.

Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Hyperion Therapeutics, Inc.

HPTX SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Launches An Investigation Of The Board Of Directors Of Hyperion Therapeutics, Inc. Concerning The Sale Of The Company To Horizon Pharma

HPTX SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Launches An Investigation Of The Board Of Directors Of Hyperion Therapeutics, Inc. Concerning The Sale Of The Company To Horizon Pharma

The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Hyperion Therapeutics, Inc.

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Hyperion Therapeutics, Inc. And Encourages Investors To Contact The Firm For Additional Information

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Hyperion Therapeutics, Inc. And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Hyperion...

Biotech Stocks? Proceed With Caution

Biotech Stocks? Proceed With Caution

Mergers are driving up biotech stocks, but beware of short traders.

HYPERION THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces The Investigation Of Hyperion Therapeutics, Inc. Over The Proposed Sale Of The Company To Horizon Pharma, Plc. - HPTX

HYPERION THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces The Investigation Of Hyperion Therapeutics, Inc. Over The Proposed Sale Of The Company To Horizon Pharma, Plc. - HPTX

Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Hyperion Therapeutics, Inc.

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation Of The Board Of Directors Of Hyperion Therapeutics, Inc.

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation Of The Board Of Directors Of Hyperion Therapeutics, Inc.

Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Hyperion Therapeutics, Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Hyperion Therapeutics, Inc. Of Commencement Of An Investigation In Connection With The Fairness Of The Sale Of The Company To Horizon Pharma

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Hyperion Therapeutics, Inc. Of Commencement Of An Investigation In Connection With The Fairness Of The Sale Of The Company To Horizon Pharma

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities Who Purchased Hyperion Therapeutics, Inc.

Big Pharma Merger Monday Deals Disregard Biotech Bubble Talks

Big Pharma Merger Monday Deals Disregard Biotech Bubble Talks

Large pharmas continued the shopping spree, paying no attention to whispers of a biotech bubble.

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Hyperion Therapeutics, Inc. And Encourages Investors To Contact The Firm For Additional Information

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Hyperion Therapeutics, Inc. And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Hyperion...

Stock Markets Soar on Trifecta of Good News

Stock Markets Soar on Trifecta of Good News

Stocks recapture positive territory for the year on a spate of pharma deals, as well as positive news from the Fed and China.

HYPERION THERAPEUTICS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Sale To Horizon Pharma

HYPERION THERAPEUTICS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Sale To Horizon Pharma

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Hyperion...

Energy Sector Leads Stock Markets Higher as Rally Rolls On

Energy Sector Leads Stock Markets Higher as Rally Rolls On

Stocks recapture positive territory for the year.

Teva Buys Tourette Syndrome Drug Firm Auspex for $3.2 Billion

Teva Buys Tourette Syndrome Drug Firm Auspex for $3.2 Billion

The Israeli drug company thinks the biopharmaceutical drug developer will strengthen its position in its core central nervous system segment.

Street Check: Hyperion Bought After Brean Noted Takeout Potential Last Month

Street Check: Hyperion Bought After Brean Noted Takeout Potential Last Month

Shares of Hyperion Therapeutics rose 8% this morning after the company announced that it had agreed to be acquired for $46 per share by Horizon Pharma.

Teva Pharmaceutical Swallows Auspex to Strengthen Its Drug Pipeline

Teva Pharmaceutical Swallows Auspex to Strengthen Its Drug Pipeline

Israeli drug company Teva Pharmaceutical Industries is buying Auspex Pharmaceuticals, with its portfolio of drugs to treat Tourette Syndrome, Huntington's chorea and a variety of other maladies.

Stocks Reclaim Year-to-Date Gains as China Talks Monetary Easing

Stocks Reclaim Year-to-Date Gains as China Talks Monetary Easing

Stocks begin the holiday-shortened week with a bounce following a deluge of big pharma M&A deals on Monday morning.